| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer (NCT00489359) | Eli Lilly and Company | 2005-07-01 |
| Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) (NCT00129727) | Massachusetts General Hospital | 2005-06-01 |
| EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide (NCT00132522) | EMD Serono | 2005-05-01 |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine (NCT00293293) | Masonic Cancer Center, University of Minnesota | 2005-05-01 |
| FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer (NCT00085527) | University of Chicago | 2005-05-01 |
| Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer (NCT00217568) | Fred Hutchinson Cancer Center | 2005-05-01 |
| Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors (NCT00274950) | Children's Cancer and Leukaemia Group | 2005-05-01 |
| Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (NCT00189553) | ARCAGY/ GINECO GROUP | 2005-04-01 |
| Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma (NCT00179712) | Celgene Corporation | 2005-04-01 |
| Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma (NCT00040911) | Children's Oncology Group | 2005-04-01 |
| An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer (NCT00113607) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-04-01 |
| Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer (NCT00118300) | Case Comprehensive Cancer Center | 2005-04-01 |
| Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer (NCT00295945) | University of California, San Francisco | 2005-03-01 |
| Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer (NCT00316173) | GlaxoSmithKline | 2005-03-01 |
| Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 (NCT04461457) | Vastra Gotaland Region | 2005-02-05 |
| A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed (NCT00097019) | Genentech, Inc. | 2005-02-01 |
| Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer (NCT00699907) | University of Arizona | 2005-01-01 |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00114166) | Gynecologic Oncology Group | 2005-01-01 |
| Campath-1H + FK506 and Methylprednisolone for GVHD (NCT00109993) | Case Comprehensive Cancer Center | 2005-01-01 |
| A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT00096993) | Genentech, Inc. | 2005-01-01 |
| Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer (NCT00102622) | M.D. Anderson Cancer Center | 2004-12-01 |
| GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer (NCT00157573) | Massachusetts General Hospital | 2004-12-01 |
| CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00096239) | Jonsson Comprehensive Cancer Center | 2004-12-01 |
| Gemcitabine in Ovarian Cancer (NCT00191334) | Eli Lilly and Company | 2004-12-01 |
| Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT00138242) | Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center | 2004-12-01 |
| 11C Topotecan PET Imaging (NCT00253461) | Case Comprehensive Cancer Center | 2004-12-01 |
| Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer (NCT00097409) | GlaxoSmithKline | 2004-12-01 |
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00112957) | Ludwig Institute for Cancer Research | 2004-12-01 |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma (NCT00082212) | Eli Lilly and Company | 2004-11-01 |
| Sexual Functioning After Primary Treatment of Ovarian Cancer (NCT00596544) | Memorial Sloan Kettering Cancer Center | 2004-11-01 |
| CT-2106 for the Second Line Treatment of Ovarian Cancer (NCT00291837) | CTI BioPharma | 2004-11-01 |
| Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer (NCT00030706) | Montefiore Medical Center | 2004-11-01 |
| Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer (NCT00101257) | Fred Hutchinson Cancer Center | 2004-10-01 |
| Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant (NCT00293384) | Barbara Ann Karmanos Cancer Institute | 2004-10-01 |
| Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries (NCT00098800) | University of Arizona | 2004-10-01 |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00317772) | M.D. Anderson Cancer Center | 2004-09-02 |
| A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer (NCT00461786) | Eli Lilly and Company | 2004-09-01 |
| Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00091377) | MEI Pharma, Inc. | 2004-08-01 |
| Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00287859) | Masonic Cancer Center, University of Minnesota | 2004-08-01 |
| Preference Study With Elderly Patients Recurrent Ovarian Cancer (NCT00170690) | North Eastern German Society of Gynaecological Oncology | 2004-08-01 |
| PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (NCT00088413) | National Cancer Institute (NCI) | 2004-07-21 |
| Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00087087) | Gynecologic Oncology Group | 2004-07-01 |
| Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00288275) | Precision Therapeutics | 2004-07-01 |
| Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment (NCT00086632) | Unither Pharmaceuticals | 2004-07-01 |
| Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00086892) | Gynecologic Oncology Group | 2004-06-01 |
| Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer (NCT00170625) | North Eastern German Society of Gynaecological Oncology | 2004-06-01 |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT00217529) | Fred Hutchinson Cancer Center | 2004-06-01 |
| Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer. (NCT00620243) | Memorial Sloan Kettering Cancer Center | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer (NCT00091273) | University of Virginia | 2004-06-01 |
| NYU Ovarian Cancer Early Detection Program Blood and Genetics (NCT00531778) | NYU Langone Health | 2004-06-01 |
| Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors (NCT00078845) | M.D. Anderson Cancer Center | 2004-05-01 |
| Clinical Benefit of Topoisomerase Downregulation (NCT00250094) | New Mexico Cancer Research Alliance | 2004-05-01 |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients (NCT00189345) | AGO Study Group | 2004-05-01 |
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels (NCT00083928) | Ångstrom Pharmaceuticals | 2004-05-01 |
| Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00408590) | Mayo Clinic | 2004-04-19 |
| Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer (NCT00245050) | Case Comprehensive Cancer Center | 2004-04-01 |
| Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer (NCT00084448) | Gynecologic Oncology Group | 2004-04-01 |
| Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse (NCT00189566) | ARCAGY/ GINECO GROUP | 2004-04-01 |
| Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00098878) | NHS Greater Glasgow and Clyde | 2004-03-01 |
| Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer (NCT00287885) | Masonic Cancer Center, University of Minnesota | 2004-03-01 |
| Internet-based System for Cancer Patients to Self-report Toxicity (NCT00578006) | Memorial Sloan Kettering Cancer Center | 2004-03-01 |
| CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen (NCT00305838) | Mount Vernon Cancer Centre at Mount Vernon Hospital | 2004-03-01 |
| A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) (NCT00709462) | Celldex Therapeutics | 2004-03-01 |
| Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer (NCT00227721) | Robert Morris | 2004-02-01 |
| Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer (NCT00337233) | Wake Forest University Health Sciences | 2004-01-01 |
| UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00072267) | University Health Network, Toronto | 2004-01-01 |
| The Development of Human Immunologic Assays Specific to Folate Receptor Antigen (NCT00155935) | National Taiwan University Hospital | 2004-01-01 |
| Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer (NCT00216112) | Daniela Matei, MD | 2003-12-01 |
| Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer (NCT00460200) | Jonsson Comprehensive Cancer Center | 2003-12-01 |
| Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer (NCT00072410) | Ludwig Institute for Cancer Research | 2003-11-01 |
| Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer (NCT00113789) | Amgen | 2003-10-01 |
| Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer (NCT00181688) | Massachusetts General Hospital | 2003-10-01 |
| Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer (NCT00090610) | Duke University | 2003-10-01 |
| Letrozole in Patients With Ovarian Tumors (NCT00505661) | M.D. Anderson Cancer Center | 2003-09-01 |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT00063401) | Eli Lilly and Company | 2003-09-01 |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00075712) | Royal College of Obstetricians and Gynecologists | 2003-09-01 |
| Elizabeth Registry for Low Grade Ovarian Cancer (NCT00345709) | M.D. Anderson Cancer Center | 2003-09-01 |
| A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer (NCT00585052) | University of Iowa | 2003-08-01 |
| Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors (NCT00070096) | Memorial Sloan Kettering Cancer Center | 2003-08-01 |
| Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk (NCT00043472) | National Cancer Institute (NCI) | 2003-07-09 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors (NCT00066651) | National Cancer Institute (NCI) | 2003-07-01 |
| Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer (NCT00075543) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2003-07-01 |
| Taxol Carboplatin and Erythropoetin (NCT00158379) | North Eastern German Society of Gynaecological Oncology | 2003-07-01 |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response (NCT00103545) | AGO Study Group | 2003-07-01 |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00066729) | Ludwig Institute for Cancer Research | 2003-06-23 |
| CA-125 in Screening Patients at High Risk for Ovarian Cancer (NCT00080639) | University of Alabama at Birmingham | 2003-06-01 |
| MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer (NCT00401674) | National Cancer Institute, Naples | 2003-06-01 |
| Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation (NCT00064311) | National Institutes of Health Clinical Center (CC) | 2003-06-01 |
| A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer (NCT00058552) | Genentech, Inc. | 2003-05-01 |
| Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma (NCT00653328) | Vanderbilt-Ingram Cancer Center | 2003-05-01 |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors (NCT00471432) | NCIC Clinical Trials Group | 2003-04-04 |
| S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00053833) | SWOG Cancer Research Network | 2003-04-01 |
| PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer (NCT00059618) | M.D. Anderson Cancer Center | 2003-04-01 |
| A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer (NCT00073541) | EMD Serono | 2003-04-01 |
| Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations (NCT00579007) | Memorial Sloan Kettering Cancer Center | 2003-03-11 |
| Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer (NCT01439659) | M.D. Anderson Cancer Center | 2003-02-18 |
| Weekly Topotecan Therapy in Patients With Ovarian Cancer (NCT00194935) | Weill Medical College of Cornell University | 2003-02-01 |
| Genetic Counseling in African American Women (NCT00419510) | University of Pennsylvania | 2003-02-01 |
| MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer (NCT00326456) | National Cancer Institute, Naples | 2003-01-01 |
| Tumor Gene Expression in Women With Ovarian Cancer (NCT00817479) | University of Chicago | 2003-01-01 |